Advances in radiopharmaceuticals for precision medicine: A global and Chinese perspective
Radiopharmaceuticals have become indispensable tools in precision medicine, revolutionizing diagnostic imaging and targeted therapeutic strategies. This manuscript provides an overview of advancements globally and in China, focusing on the classification and clinical applications of radiopharmaceuticals, particularly in oncology and neurology. Recent progress includes PET/SPECT diagnostic agents and therapeutic radionuclides that provide precise treatment while limiting damage to healthy tissues. Emerging technologies, such as artificial intelligence, novel ligands, advanced radionuclides, and combination therapies, present promising avenues to further enhance the efficacy and accessibility of the field. Despite these achievements, challenges remain in production, regulatory, and costs, underscoring the need for ongoing innovation and international collaboration to fully realize the potential of radiopharmaceuticals in personalized healthcare and optimize patient outcomes.
Authors
- Qingqing Huang (ORCID: https://orcid.org/0000-0001-7080-7588)
- Gang Huang (ORCID: https://orcid.org/0000-0003-3936-9123)
Institutions
- Jiading District Central Hospital (CN)
- Shanghai University of Medicine and Health Sciences (CN)
Publication Details
- Journal
- LabMed discovery.
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1016/j.lmd.2024.100031
- Citations
- 8
- Primary Topic
- Radiopharmaceutical Chemistry and Applications
- Type
- article
- Field-Weighted Citation Impact
- 3.23
Funders
- National Natural Science Foundation of China
- Shanghai Key Laboratory of Molecular Imaging
- National Key Research and Development Program of China
- National Key Research and Development Program of China Stem Cell and Translational Research